| Ytd | -12.60% | |
| 1y | 2.23% |
| Open | 3.51 | Prev Close | 3.54 | Low | 3.43 | High | 3.51 | Mkt Cap | 211.66M |
| Vol | 79.27K | Avg Vol | 596.78K | EPS | -1.81 | P/E | N/A | Forward P/E | -3.41 |
| Beta | 1.31 | Short Ratio | 4.44 | Inst. Own | 65.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 3.34 | 200-d Avg | 3.79 | 1yr Est | 17.10 |
VYGR News
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR)
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.40) per share which beat the ana
- Data presented as Developing Topics poster at AAIC 2026 -LEXINGTON, Mass., July 13, 2026 (GLOBE NE
Jim Cramer recommended buying GE Vernova Inc. as Bernstein analyst initiated coverage with an Outper
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.47) per share which beat the ana
- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, d
https://www.sec.gov/ix?doc=/Archives/edgar/data/1640266/000110465926045997/tm2612325d1_8k.htm
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR)
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.46) per share which beat the ana
Johnson & Johnson ends its Phase 2b posdinemab trial after missing key Alzheimer's goals, ra
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Voyager Therapeutics (NASDAQ:VYGR)
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.47) per share which beat the ana
Voyager's Alzheimer's programs show longer CNS exposure and potential gene therapy advances,
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR)
Wedbush analyst Yun Zhong maintains Voyager Therapeutics (NASDAQ:VYGR) with a Outperform and lowe
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.57) per share which missed the a
New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carrier
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics t
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.53) per share which missed the a
HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) wi
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and p
Canaccord Genuity analyst Sumant Kulkarni maintains Voyager Therapeutics (NASDAQ:VYGR) with a Buy
HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) wi
Wells Fargo analyst Yanan Zhu maintains Voyager Therapeutics (NASDAQ:VYGR) with a Overweight and
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Voyager Therapeutics (NASDAQ:VYGR) from Ov
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.59) per share which missed the a
HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) wi
Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pha
HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) wi
Citigroup analyst Samantha Semenkow initiates coverage on Voyager Therapeutics (NASDAQ:VYGR) with
Canaccord Genuity analyst Sumant Kulkarni maintains Voyager Therapeutics (NASDAQ:VYGR) with a Buy
HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) wi
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.16) per share which beat the ana
HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) wi
Leerink Partners analyst Lili Nsongo initiates coverage on Voyager Therapeutics (NASDAQ:VYGR) wit
Selection of the development candidate triggered a $3 million milestone payment to Voyager, which th